Abstract
Vitamins are prominent among natural or endogenous compounds that are considered to be beneficial for both prevention and therapy of various human ailments. The vitamin E group of compounds composed of tocopherol and tocotrienol isoforms, has been subsequently proven to have health benefits including antioxidant and related protective properties. However, individual isoforms exhibit a wide-range of antioxidant potencies. Tocotrienol (T3) displays powerful anticancer activity that is often not exhibited by tocopherols, by modulating multiple intracellular signaling pathways associated with tumor cell proliferation and survival. The anticancer effect of T3 remains not fully understood but generally is mediated independently of its antioxidant activity. Further we have synthesized a new redox-inactive analogue of T3, 6-O-carboxypropyl-α-tocotrienol (T3E) showing considerable promise for stronger anticancer potency than its mother compound. In this mini-review, we particularly focus upon the anticancer action of the above active components of vitamin E and describe current research on the anticancer effects of T3 irrespective of antioxidant activity.
Keywords: Redox-inactive analogue, Tocotrienol, Anticancer activity, Non-antioxidant
Anti-Cancer Agents in Medicinal Chemistry
Title:Redox-inactive Analogue of Tocotrienol as a Potential Anti-cancer Agent
Volume: 13 Issue: 3
Author(s): Tomohiro Yano, Ayami Sato, Miki Sekine, Nantiga Virgona and Masako Ota
Affiliation:
Keywords: Redox-inactive analogue, Tocotrienol, Anticancer activity, Non-antioxidant
Abstract: Vitamins are prominent among natural or endogenous compounds that are considered to be beneficial for both prevention and therapy of various human ailments. The vitamin E group of compounds composed of tocopherol and tocotrienol isoforms, has been subsequently proven to have health benefits including antioxidant and related protective properties. However, individual isoforms exhibit a wide-range of antioxidant potencies. Tocotrienol (T3) displays powerful anticancer activity that is often not exhibited by tocopherols, by modulating multiple intracellular signaling pathways associated with tumor cell proliferation and survival. The anticancer effect of T3 remains not fully understood but generally is mediated independently of its antioxidant activity. Further we have synthesized a new redox-inactive analogue of T3, 6-O-carboxypropyl-α-tocotrienol (T3E) showing considerable promise for stronger anticancer potency than its mother compound. In this mini-review, we particularly focus upon the anticancer action of the above active components of vitamin E and describe current research on the anticancer effects of T3 irrespective of antioxidant activity.
Export Options
About this article
Cite this article as:
Yano Tomohiro, Sato Ayami, Sekine Miki, Virgona Nantiga and Ota Masako, Redox-inactive Analogue of Tocotrienol as a Potential Anti-cancer Agent, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (3) . https://dx.doi.org/10.2174/1871520611313030012
DOI https://dx.doi.org/10.2174/1871520611313030012 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advancements in Carbon Nanofiber and Carbon Nanotube Applications in Drug Delivery and Tissue Engineering
Current Pharmaceutical Design Cox Inhibitors as Potential Chemotherapic Drugs for Mesothelioma
Current Respiratory Medicine Reviews Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Lung Cancer: Are we up to the Challenge?
Current Genomics Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells
Current Drug Targets Idronoxil as an Anticancer Agent: Activity and Mechanisms
Current Cancer Drug Targets TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Utilising Nanotechnology and Nanosystems for Treatment of Rare Diseases
Pharmaceutical Nanotechnology MDA-7/IL-24-Based Cancer Gene Therapy: Translation from the Laboratory to the Clinic
Current Gene Therapy Hypoxia and Inflammation in Prostate Cancer Progression. Cross-talk with Androgen and Estrogen Receptors and Cancer Stem Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Reversing Aberrant Methylation Patterns in Cancer
Current Medicinal Chemistry Epidemiology, Clinical Presentation and Treatment of Uveal Melanoma
Clinical Cancer Drugs Proton Ion-Microbeam Elemental Analysis for Inhaled Particle-Induced Pulmonary Diseases: Application for Diagnosis and Assessment of Progression
Current Medicinal Chemistry Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus
Current Cancer Drug Targets Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment
Current Drug Metabolism Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry Editorial [Hot topic: The Role of Pemetrexed in Lung Cancer (Guest Editors: Daoyuan Wang and Jianxing He)]
Current Drug Targets